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Background: Studies have shown that certain Internet interventions can help alleviate depression. However,
many such interventions contain personal support elements,making it difﬁcult to ascertainwhether theprogram
or the support drives the effects. Studies are needed to investigate whether Internet interventions contribute to
symptom reduction even when they are delivered without personal support, and even among severely de-
pressed individuals who often receive other forms of treatment.
Objective: This randomized controlled trial aimed to examine the effect of an Internet intervention that was de-
ployed without personal support (“Deprexis”) among adults with initially severe depression symptoms.
Methods: Adults recruited from a range of sources who had exceeded the threshold for severe depression (PHQ-
9≥ 15) in a pre-screening assessment andmet inclusion criteriawere randomized (N=163) to the intervention
(3 months program access; n=78) or care-as-usual/waitlist control (n=85). A diagnostic screening interview
was administered by telephone at baseline to all participants. Online assessments were administered at baseline,
3 months (post-treatment), and 6months (follow-up). Themain outcomewas the Patient Health Questionnaire
(PHQ-9) between baseline and post-treatment.
Results: Eighty-two percent of randomized participants were reached for the post-treatment assessment. Results
for the intention-to-treat (ITT) sample showed signiﬁcant intervention effects on depression reduction between
baseline and post-treatment (linear mixed model [MM], F1,155.6 = 9.00, p b .01, for the time by condition inter-
action), with a medium between-group effect size, Cohen's d = 0.57 (95% CI: 0.22–0.92). Group differences in
depression severity at follow-up were marginally signiﬁcant in the ITT sample, t (119) = 1.83, p = 0.07, and
smaller than at post-treatment (PHQ-9, d= 0.33, 95% CI:−0.03–0.69). The number needed to treat (NNT) at
post-treatment was 5, with 38% of participants in the intervention group achieving response (at least 50%
PHQ-9 symptom change, plus post-treatment score b10), compared to 17% in the control group, p b 0.01. Effects
on secondary outcomes, including anxiety, health-related quality of life, and somatic symptoms, were not signif-
icant, with the exception of signiﬁcant effects on anxiety reduction in PP analyses. Early ratings of program, Gertigstr. 12-14, 22303 Hamburg, Germany. Tel.: +49 40 3510 5231; fax: +49 40 3510 5210.
yer).
. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
49B. Meyer et al. / Internet Interventions 2 (2015) 48–59helpfulness/alliance (after 3 weeks) predicted pre–post depression reduction, controlling for baseline severity
and early symptom change.
Conclusions: These results replicate and extend previous ﬁndings by showing that Deprexis can facilitate symp-
tomatic improvement over 3 months and, perhaps to a lesser degree, up until 6 months among adults with ini-
tially severe depression.© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Over the past decade, at least 25 randomized controlled trials (RCTs)
and several systematic reviews and meta-analyses have demonstrated
that Internet interventions can reduce depression symptoms among
program users and thereby contribute to improving the quality of care
for persons with unipolar depression (Andersson and Cuijpers, 2009;
Andrews and Titov, 2010; Andrews et al., 2010; Barak et al., 2008;
Cuijpers et al., 2011; Johansson and Andersson, 2012; Richards and
Richardson, 2012). Consensus seems to be emerging that well-
designed depression-focussed Internet interventions are efﬁcacious,
and that more relevant research challenges now concern the identiﬁca-
tion of moderators and mediators, health economic evaluations, the
transfer of interventions to routine care settings, and exploring combi-
nations of Internet interventions with pharmaceutical or face-to-face
psychotherapeutic treatments (Andersson and Titov, 2014).
This positive appraisal of the research evidence has been expressed
enthusiastically in recent years (Andrews and Titov, 2010; Titov, 2011;
Kazdin and Blase, 2011), although it is not shared by all. For example,
a recent review noted several methodological shortcomings plaguing
this ﬁeld, including the scarcity of non-inferiority comparisons with
established treatments, the absence of valid diagnostic procedures and
outcome assessments beyond self-report, and the predominant focus
on short-term effects (Arnberg et al., 2014). Moreover, most currently
studied interventions come from a small number of countries, particu-
larly from research groups in Sweden, Australia, and the Netherlands
(Arnberg et al., 2014), although others may be catching up.
Questions also remainwith regard to themerit of purely stand-alone
interventions, which are typically associated with smaller effect sizes,
compared to programs that are accompanied by personal support
(e.g., “blended”, “guided”, or “supported” online interventions)
(Johansson and Andersson, 2012; Richards and Richardson, 2012). As
Kazdin and Blase remarked (Kazdin and Blase, 2011), though, “the arbi-
ter of the value of a treatment is not necessarily in its effect size… but
where that intervention ﬁts into a broader portfolio to help reduce the
burden ofmental illness” (p. 29). Conceivably, unsupported orminimal-
ly supported interventions could also play a useful role, especially when
combined with available treatments, although little research has ad-
dressed this issue. Interestingly, recent research also suggests that the
effectiveness of unsupported interventions can be enhanced by inte-
grating automated forms of support, such as regular reminder e-mails
(Titov et al., 2013), so there are several good reasons for continuing to
investigate such programs. Our goal in this study, therefore, was to fur-
ther examine the beneﬁts of an unsupported version of an Internet-
based depression intervention in a trial that has several methodological
improvements over earlier studies.
In previous work, members of our research group have developed
and examined a depression-focussed Internet intervention that has
been studied in three published RCTs (Berger et al., 2011; Meyer et al.,
2009; Moritz et al., 2012): the Deprexis program. We regard the results
from these trials as encouraging, particularly when compared with
other “self-guided” (i.e., unsupported) Internet interventions (Cuijpers
et al., 2011). The Deprexis program is primarily cognitive–behavioural
in content focus but also includes integrative elements, such as accep-
tance and mindfulness, interpersonal relatedness, positive psychology,
and the facilitation of basic psychological needs (Meyer et al., 2009). Itcan be deployed both in an unsupported (Meyer et al., 2009; Moritz
et al., 2012) or a supported version (Berger et al., 2011), which allows
clinicians to track program use and symptom trajectories in order to in-
tervene accordingly. There is a need to replicate the program's effects in
methodologically stringent trials, as previous studies have suffered from
shortcomings such as lack of diagnostic interviews (Meyer et al., 2009;
Moritz et al., 2012), small sample sizes (Berger et al., 2011), or high at-
trition rates (Meyer et al., 2009).
There is also a need to examine in more detail whether Internet in-
terventions such as Deprexis are particularly beneﬁcial for certain pa-
tient groups, such as those with milder versus more severe symptoms
or with versus without concurrent treatment. Although Internet-based
depression interventions are often regarded as an appropriate ﬁrst
step primarily for persons presenting with mild to moderate symptoms
(National Institute for Health and Clinical Excellence, 2009), evidence
from a patient-level meta-analysis suggests that more severely de-
pressed patients might derive greater beneﬁt (Bower et al., 2013). For
severely depressed patients, personally supported rather than stand-
alone Internet interventions may seem like a more suitable option,
though, not only for ethical and safety reasons but also because they
have been found to produce larger effects, on average (Johansson and
Andersson, 2012; Richards and Richardson, 2012; Berger et al., 2011).
However, we believe that it is also important to examine the effects of
online interventions that are offered without support among the se-
verely depressed, for several reasons: Firstly, interventions that do not
require personal support resources can be offered reliably and efﬁcient-
ly to large numbers of people in need, even when resources are scarce
(Kazdin and Blase, 2011). Secondly, whereas it may be hard to tease
apart which aspects of “guided treatments” are responsible for any ob-
served clinical beneﬁts (i.e., the quality or extent of support, the thera-
peutic relationship, or the software itself), studying unsupported
treatments offers the possible methodological advantage of clear causal
interpretability. Thirdly, many people with severe depression already
receive some form of treatment involving personal contact – perhaps
asmany as 80% in Europe (McCracken et al., 2006) – so it seems relevant
to ask whether offering an Internet intervention as an additional tool
might have an incremental or synergistic effect when combined with
treatments patients already receive.
The goal of the present trial, then, was to examine the effects of the
Deprexis program among adults screened for severe depression symp-
toms in amoderately sized pragmatic RCT. A large and publically funded
RCT (N1000 participants) focussing on the program's effects among
peoplewithmild tomoderate depression symptoms is currently under-
way (the EVIDENT trial (Klein et al., 2013)). However, participants with
severe symptoms were not admitted for participation in that trial, even
though Internet interventions may be most beneﬁcial among more se-
verely depressed persons (Bower et al., 2013). Therefore, the present
trial was initiated for those who had expressed interest in participating
in the EVIDENT trial but did not meet inclusion criteria due to scoring
above the severity threshold on a screening questionnaire, as described
below.
As a pragmatic trial (Zwarenstein et al., 2008), the present RCT
aimed to test whether offering Deprexis to this group, above and be-
yond any to standard care they might receive, would reduce depression
severity at a greater rate thanwhatwould be observedwithout this pro-
gram (i.e. in a control group). We also aimed to examine secondary
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quality of life, and to examine whether early perceptions of program
helpfulness would predict pre–post symptom reduction.
2. Method
2.1. Participants
Participants who had expressed interest in participating in the
EVIDENT trial (Klein et al., 2013) but were excluded from it because
their depression symptoms were beyond the mild to moderate range
(that is, N14 on PHQ-9) were automatically referred to a separate
study website on which the goals of the study were explained, and
they were asked to complete a baseline questionnaire. In the EVIDENT
trial, participants were recruited from a broad range of settings, includ-
ing outpatient and inpatient treatment clinics, Internet depression fo-
rums, health insurances, and newspaper advertisements (Klein et al.,
2013). Participants were included in the present trial if they surpassed
the PHQ-9 score of 14 in the EVIDENT screening, even if they no longer
scored above this threshold at the baseline assessment.
Inclusion criteria were: age 18–65, ability to read German, willing-
ness to participate in a telephone diagnostic interview, score of 15 to
27 (i.e., no upper limit) on the PHQ-9 in the initial screening described
above, and written informed consent. Exclusion criteria were a lifetime
diagnosis of schizophrenia or bipolar disorder (as determined by a tele-
phone diagnostic interview) or current suicidality (as determined in the
telephone interview; see below).
2.2. Procedure and study design
This was a parallel-group pragmatic randomized controlled trial.
Participants were randomized to two groups: (1) Care-as-usual (CAU)
or (2) CAU plus the Internet intervention (i.e. access to the Deprexis
program for 3 months). Participants randomized to the treatment
group were invited to use the online intervention without guidance or
support. That is, there was no contact between participants and study-
related personnel, with the exception of the pre-randomization
telephone-administered diagnostic screening interview. This design
was chosen because it allowed us to evaluate the intervention effect in
relatively pure form, without the potential boost conferred by personal
support or the therapeutic relationship, while retaining the advantage
of collecting valid diagnostic information from a structured interview.
Diagnostic status (presence of current Major Depressive Episode
(MDE) or Dysthymic Disorder (DD) according to DSM-IV criteria) was
determined with the Mini International Neuropsychiatric Interview
(MINI (Lecrubier et al., 1997)), which was administered via telephone
by trained interviewers with a university degree in psychology who
were in advanced professional training to become licensed psychother-
apists. TheMINI has been shown to be an efﬁcient tool that can help im-
prove the accuracy of diagnoses, compared to routine physician
diagnoses, which are often unreliable (Pinninti et al., 2003; Mitchell
et al., 2009). The MINI was also used to conﬁrm the absence of clinical
exclusion criteria (likely diagnosis of schizophrenia or bipolar disorder,
or suicidality). To ensure patient safety, a personal emergency plan was
also discussed with each participant during the telephone interview.
That is, emergency contact options were discussed, including the con-
tact details of local psychiatrists, physicians and clinics, as well as emer-
gency telephone hotlines.
Randomization was conducted with an allocation schedule of ran-
dom numbers that was created by a computerized random number
generator. Participants who were deemed eligible after the telephone
interview were consecutively placed on this list by one of the re-
searchers (J.B.), who did not conduct telephone interviews and did not
have contact with or knowledge of individual study participants. Partic-
ipants were informed of the outcome of the randomization by a stan-
dard e-mail, in which those in the treatment condition received theiraccess voucher that enabled them to log onto the intervention and use
it freely (without time-limit and at no cost) for a subsequent 90 day
period.
The study was approved by the ethics committee of the German
Psychological Association (DGPs, reference number SM 042012_amd_122012),
and the trial was entered in an international trials registry (NCT02178631 at
ClinicalTrials.gov). Before providing consent, all participants received
written information about the aims and procedures used in the study
and were informed that they could withdraw at any point without
negative consequences. The study was conducted in compliance
with the Declaration of Helsinki (World Medical Association, 2001)
and took place between 02/2013 and 04/2014.
2.3. Measures
2.3.1. Primary outcome measure
Patient Health Questionnaire - 9 items (PHQ-9; (Gräfe et al., 2004;
Kroenke et al., 2001; Löwe et al., 2004; Martin et al., 2006)). The PHQ-
9, one of themost thoroughly validated self-report scales for the assess-
ment of depressive symptom severity, serves as the primary outcome
measure in the EVIDENT trial (Klein et al., 2013) and, therefore, was
also selected as the primary outcome for the present trial. The psycho-
metric properties of the PHQ-9 are excellent, with high internal consis-
tency, test–retest reliability, criterion validity, comparatively favourable
sensitivity and speciﬁcity, and good sensitivity to change (Kroenke et al.,
2010). The PHQ-9, as well as all other measures, was administered via
an online survey platform, as there is evidence that this produces valid
results and offers the advantage of efﬁciency (van Gelder et al., 2010;
Fann et al., 2009). Clinically signiﬁcant improvement on the PHQ-9
can be deﬁned as a ﬁve-point decline (Löwe et al., 2004; Kroenke
et al., 2010) or 50% decline plus post-treatment score below 10
(McMillan et al., 2010).
2.3.2. Secondary outcome measures
Generalized Anxiety Disorder - 7 (GAD-7) (Spitzer et al., 2006). The
GAD-7 targets symptomsof generalized anxiety disorder, which is high-
ly comorbid with depression and may share a common genetic vulner-
ability (Gorwood, 2004). The GAD-7 has been found to correlate highly
with other anxiety scales, to have a high level internal consistency
(α N .85), and to have good sensitivity and speciﬁcity for the detection
of not only GAD but also panic, social anxiety disorder and post-
traumatic stress disorders (Kroenke et al., 2010). It is frequently used
in Internet intervention trials as a generic measure of anxiety severity
(Johansson et al., 2012; Titov et al., 2011; Dear et al., 2011).
Patient Health Questionnaire - 15 items (PHQ-15) (Kroenke et al.,
2002). The PHQ-15 is an efﬁcient measure of somatic complaints that
are commonly encountered in primary care and in the general popula-
tion,which are also frequently comorbidwith both depression and anx-
iety. As summarized in a recent review, the PHQ-15's psychometric
properties are adequate, as evidenced by acceptable internal consisten-
cy (α around .80); good convergent validity with measures of function-
ing, symptom burden and healthcare utilization, and good sensitivity to
change (Kroenke et al., 2010). The PHQ-15 can be regarded as ameasure
of somatic symptom severity aswell as potential somatization (Kroenke
et al., 2010; Kroenke et al., 2002).
Short Form Health Survey - 12 (SF-12) (Ware et al., 1996). The SF-12
is a commonly used measure of general health functioning or health-
related quality of life and yields two summary scores: a physical and a
mental health index. The SF-12 has been validated internationally and
is commonly used in epidemiological surveys, although it has also
been used among patients with psychiatric illness, including depression
(Sugar et al., 1998; Gandek et al., 1998; Salyers et al., 2000). Psychome-
tric properties, including test–retest reliability, internal consistency and
convergent validity are good to excellent, and comparable to its longer
version, the SF-36 (Gandek et al., 1998; Jenkinson et al., 1997).
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An adapted version of a patient satisfaction questionnaire that is
widely used in Germany, the ZUF-8 (Schmidt et al., 1989), was used in
this study. This brief and reliable instrument was originally developed
as a translation of the Client Satisfaction Questionnaire (CSQ-8
(Attkisson and Greenﬁeld, 1999)) and was originally intended to assess
satisfaction with inpatient treatment. The itemswere reworded slightly
to focus on satisfaction with the Internet intervention examined in this
trial.
We also administered an adapted version of the 11-itemHelping Al-
liance Questionnaire (HAQ-11 (Alexander and Luborsky, 1986; Bassler
et al., 1995)) three weeks after randomization to participants allocated
to the treatment group. The HAQ-11 yields either a total score (used
here) or two subscale scores, indicating the extent to which patients
feel that the treatment is helpful, seems to view problems in the same
way and seems to share their goals. A six-point response scale was
used, with values of−1 to−3 indicating negative alliance/helpfulness
perceptions, whereas values of +1 to +3 indicate positive alliance/
helpfulness perceptions. The mean of 11 items was computed to indi-
cate patients' impressions of alliance/helpfulness early. The HAQ is
one of the most commonly used alliance questionnaires and has been
found to have good psychometric properties and predict various aspects
of psychotherapeutic process and outcome, although it is not always
clear whether the alliance, as measured by scales such as the HAQ, is a
reﬂection of third variables, such as early symptom improvement, rath-
er than an independent predictor of process and outcome (Elvins and
Green, 2008).
2.4. Treatment
The Deprexis program is an integrative Internet intervention for
adults with symptoms of unipolar depression (Meyer et al., 2009), de-
veloped and operated by a research-focussed public health company
in Hamburg, Germany (Gaia). The program uses a software technology
(broca®) that was designed to allow for the tailoring of content to dy-
namically changing user requirements. To accomplish this, the core of
the program revolves around a series of “simulated dialogues” in
which patients are continuously asked to select one of several response
options, after which the program then presents content to match the
chosen response. Content covered in these “dialogues” ranges from tra-
ditional cognitive–behavioural topics, such as cognitive restructuring,
behavioural activation, problem-solving, and acceptance/mindfulness
to optional topics such as positive psychology and emotion-focussed
techniques (for a more detailed description, see Meyer et al. (2009);
Meyer et al. (2009)).
The Deprexis program in its current version also includes daily text
(SMS) messages that are deployed optionally and convey content that
has been covered in the program. If users consent, they receive a differ-
ent daily message for 3 months, which is intended to brieﬂy remind
them of key ideas conveyed by the program and encourage them to
apply these techniques in their current situational context (Examples:
(a) “Which thoughts are going through your mind right now? Are
they helpful? If so, let them be! If not, let them go calmly”; (b) “Helpful
response to mistakes: ‘I've made a mistake, which is normal and
human!’ Support yourself compassionately…”). Additionally, the pro-
gram integrates features such as symptom-tracking (e.g., question-
naires such as the PHQ-9 are offered in two-week intervals and
graphical as well as text feedback is provided), worksheets and summa-
ries in printable format, audio recordings, and photos as well as illustra-
tions. The program has been CE-certiﬁed as amedical product in Europe
and is currently available in German, English and Swedish language ver-
sions. Previous trials have demonstrated the program's effectiveness
(Berger et al., 2011; Meyer et al., 2009; Moritz et al., 2012), and
above-average effects have been found for the program in meta-
analyses (Cuijpers et al., 2011; Richards and Richardson, 2012). Partici-
pants in the Deprexis group were also permitted to use whichevercomponents of care-as-usual (CAU) were available to them, including
pharmacotherapy and/or psychotherapy (just as in the control
condition).
2.5. Control condition
Participants in the control conditionwere not inﬂuenced or advised to
change their existing treatment patterns (that is, they received CAU).
They were informed that they could receive access vouchers to the
Deprexis program after the study period of 6 months, if they wished.
Therefore, with respect to gaining access to Deprexis, this is a waitlist
control condition, albeit with the caveat that participants were permitted
to use any other treatments available to them. This CAU plus waitlist
comparison condition was chosen in line with the logic governing prag-
matic randomized control trials: to maximize external validity and test
whether the intervention improves outcome compared to the heteroge-
neous care realities characterizingmost healthcare systems (Zwarenstein
et al., 2008). The extent to which control (and intervention) participants
used concurrent treatments, such as antidepressant medication or psy-
chotherapy, was assessed and examined.
2.6. Statistical analysis
Following current standards (Meyer et al., 2009; Mackinnon et al.,
2008; Andersson et al., 2012a; Ivarsson et al., 2014), we used a linear
mixed effects models (MM) approach with full information maximum
likelihood estimation. This approach has been recommended because
it uses all available data and can handle missing data appropriately
(Gueorguieva and Krystal, 2004). The approach is based on the assump-
tion that data are missing at random, and it is not assumed that missing
data remain stable, as in the no-longer-recommended last-observation-
carried-forward (LOCF) approach (Blankers et al., 2010). We used a
ﬁrst-order autoregressive covariance structure to model both post-
treatment and follow-up effects.
Consistent with CONSORT recommendations (Eysenbach and
CONSORT-EHEALTH Group, 2011), we report MM analyses across mul-
tiple groups: (1) The intention-to-treat (ITT) group,which includes data
from all randomized participants, regardless of whether they used the
intervention or activated their access vouchers to enter the program,
(2) the Per-Protocol (PP) group of participants in the treatment condi-
tion who had activated their vouchers, thus indicating an interest in it
(referred to as the PP-AV sample; AV: “activated voucher”), (3) the PP
sample of treatment participants who were able to engage with the in-
tervention for a reasonable amount, deﬁned here as having started at
least four sessions and spent a total of at least 60 min actively engaged
within the program (referred to as the 4S group; 4S: “at least four ses-
sions”). The deﬁnition of four sessions for reasonable intervention use
(adequate dosage) is consistent with other research groups' deﬁnitions
(Ivarsson et al., 2014). Also, completion of four sessions exposes users to
the content we deem minimally sufﬁcient (e.g. psychoeducation, be-
havioural activation, cognitive restructuring). Participants in the PP 4S
group are, therefore, considered to be adherent to the program.
We do not report analyses for participants who completed “all mod-
ules” because this number varies per user, given the tailored nature of
content delivery in Deprexis (Meyer et al., 2009). For example, whereas
core content covering behavioural activation and cognitive restructuring
is always presented early on, content on emotion-focussed interventions
is offered only for participants who indicate an express wish for such
topics. We would not expect that every user must view all content in
order to beneﬁt.
Following evidence-based recommendations,wedeﬁned response on
our primary outcomemeasure, the PHQ-9, as a post-treatment (3month)
score of below 10 combined with improvement of at least 50%, among
participants who had scored above 10 at baseline (McMillan et al.,
2010). This deﬁnition has been shown to be closely aligned with alterna-
tive approaches, such as using the reliable change criterion developed by
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pants (98%) scored above 10 on the primary outcome measure (PHQ-9)
and could, therefore, be included in the responder analyses.
Effect sizes are presented as Cohen's d throughout; that is, differ-
ences between means at post- and follow-up tests, divided by the
pooled standard deviation of the respective subsample. All effect sizes
were computed from the observed means of the respective groups
(e.g., ITT, PP-AV, PP-4S), consistent with current practices used by
other groups (Andersson et al., 2012a).
An a-priori power analysis revealed that the study was adequately
powered (i.e. N0.80) to detect a post-treatment group differences corre-
sponding to d = 0.45, which seemed realistic, given that previous re-
search has found similar effects (Johansson and Andersson, 2012;
Berger et al., 2011), particularly in studies involving pre-treatment con-
tact, such as the initial diagnostic interview employed here.
3. Results
3.1. Enrolment and baseline characteristics
As shown in Table 1, about 3 out of 4 participants were women,
and the average age was just above 40. The typical (modal) partici-
pant had completed secondary education, was not working full-Table 1
Demographic and clinical variables.
Variable Sub-variable
Gender Male
Female
Age Mean age (SD)
Range
Marital status Married
Separated
Single
In relationship
Divorced
Widowed
Education⁎ Lower secondary
Middle secondary
Higher secondary
Highest secondary
Other
Employment status Full time
Regular part-time
Not working
Recruitment source Via clinic/doctor
Internet forum
Health insurance
Other (e.g., Internet search, ne
Currently on antidepressants Yes
No
Currently in psychiatric/psychotherapeutic treatment Yes
No
Waiting for psychotherapy Yes
No
Age of depression onset Mean Age (SD)
Chronicity of depression Deﬁnitely not chronic
Unsure
Deﬁnitely chronic
Clinical diagnosis of a depressive disorder Yes
No
Diagnosis (MINI) Only MDE
Only DYS
Both MDE and DYS
Neither
Frequency of Internet use ≤3 times per week
(Almost) every day
⁎ Secondary education according to theGerman classiﬁcation: “Hauptschule” (“lower”, 9 year
(12 years, until age 17/18), “Abitur” (12 or 13 years, until age 17–19).time, and had found the study via news reports, an Internet search,
or posts in depression Internet forums. Participants were also re-
cruited via clinical settings or informed by their health insurance
companies. About half of the participants were currently receiving
antidepressant medication, and about half reported being in current
psychiatric or psychotherapeutic treatment. When asked about re-
ceiving any current treatment, 120 (74%) of the 163 randomized par-
ticipants reported either being in some form of psychiatric or
psychological treatment, taking antidepressants, or receiving psy-
chotherapy, whereas 43 (26%) reported that they currently did not
receive any such treatment.
The vast majority of enrolled subjects (84%) reported having re-
ceived a clinical diagnosis of a depressive disorder from a healthcare
provider, and most (88.3%) stated that their depression might be
(51.5%) or was deﬁnitely (36.8%) a chronic problem. On average, partic-
ipants had suffered from depression symptoms for over 15 years, given
that mean symptom onset was reported at age 25, with average current
age above 40. Nearly half (48%) reported early onset of depressive
symptoms (before age 21). Almost all (87%) reported using the
Internet almost daily, which is in line with population usage patterns:
79% of Germans above age 10 used the Internet daily or almost daily
in the ﬁrst quarter of 2013 (German Federal Statistical Ofﬁce
(Statistisches Bundesamt), 2014).Treatment Control group Total
(n = 78) (n = 85) (n = 163)
n % n % n %
20 25.6 21 24.7 41 25.2
58 74.4 64 75.3 122 74.8
44 (11.02) 40 (11.48) 42 (11.39)
21–62 18–62 18–62
28 35.9 17 20 45 27.6
5 6.4 4 4.7 9 5.5
19 24.4 29 34.1 48 29.4
14 17.9 26 30.6 40 24.5
10 12.8 9 10.6 19 11.7
2 2.6 0 0 2 1.2
4 5.1 3 3.5 7 4.3
23 29.5 14 16.5 37 22.7
14 17.9 12 14.1 26 16
37 47.4 53 62.4 90 55.2
0 0 3 3 3.5 1.8
38 48.7 31 36.5 69 42.3
9 11.5 16 18.8 25 15.3
31 39.7 38 44.7 69 42.3
11 14.1 13 15.3 24 14.7
18 23.1 23 27.1 41 25.2
13 16.7 7 8.2 20 12.3
wspaper) 36 46.2 42 49.4 78 47.9
39 50 45 52.9 84 51.5
39 50 40 47.1 79 48.5
43 55.1 45 52.9 88 54
35 44.9 40 47.1 75 46
22 28.2 24 28.2 46 28.2
56 71.8 61 71.8 117 71.8
27 (13.88) 24 (12.47) 25 (13.22)
11 14.1 8 9.4 19 11.7
40 51.3 44 51.8 84 51.5
27 34.6 33 38.8 60 36.8
66 84.6 71 83.5 137 84
12 15.4 14 16.5 26 16
29 37.2 32 37.6 61 37.2
10 12.8 7 8.2 17 10.4
29 37.2 35 41.2 64 39.3
10 12.8 11 12.9 21 12.9
12 15.4 9 10.6 21 12.9
66 84.6 76 89.4 142 87.1
s, until age 15/16), “Realschule” (“middle”, 10 years, until age 16/17), “Fachhochschulreife”
53B. Meyer et al. / Internet Interventions 2 (2015) 48–59Mean depression severity at baseline, as measured by the PHQ-9,
was in the severe range, at 16.92 (SD=3.66); 75% of participants scored
above the cut-off of 15 for severe depression; 23% scored in the moder-
ate range (10–14), and only 2% scored below 10.
There were no statistically signiﬁcant differences in any baseline de-
mographic or clinical characteristics between participants in the treat-
ment versus control groups, with the exception that those in the
treatment group were slightly older, t(161) = 2.18, p= .03. Therefore,
age was entered as a covariate in all inferential outcome analyses below
(although results were not substantially affected by this inclusion; that
is, the signiﬁcance of all ﬁndings reported below remained the same re-
gardless of whether age was included as a covariate or not).
Information collected with the MINI interview revealed that 87% of
randomized participants fulﬁlled diagnostic criteria for a current de-
pressive syndrome or disorder. Speciﬁcally, 77% met criteria for current
Major Depressive Episode (MDE), either alone (37%) or in the form of
double-depression (that is, with additional diagnosis of dysthymic dis-
order, 39%). An additional 10%met diagnostic criteria for dysthymic dis-
order but not current MDE (see Table 1). The diagnoses were
distributed evenly across the treatment versus control groups, as con-
ﬁrmed by χ2 tests, ps N .40.3.2. Patient ﬂow and treatment adherence
The numbers and percentages of retained participants at the 3- and
6-month time-points are shown in the CONSORT ﬂow chart (Fig. 1). The
attrition rate at post-treatment was 18% and can thus be considered
low, particularly for an unsupported Internet intervention. In terms of
treatment adherence, 80% (n= 56/70) of the participants in the treat-
ment condition who had activated their voucher completed at least
four sessions and used the program for a minimum of one hour and,
thus, can be regarded as treatment-adherent.285 individuals started baseline
163 participants me
Treatment Group
(n = 78) p
Completed Post-
Questionnaires 
(n=61) (78%)
Completed Follow-up (6 
Month) Questionnaires 
(n=57) (73%)
Baseline
(n = 163, 100%)
Post-treatment
(n = 134, 82%)
Follow-up
(n = 118, 72.4%)
Fig. 1. CONSORT-R partThe average (mean) time these adherent users engaged online with
the programwas estimated to be 457min (SD=240) or just over seven
and a half hours. The mean time that all users (including the non-
compliant group) who had activated their vouchers spent onlinewithin
the program was estimated to be 390 min (SD= 254) or six and a half
hours. In the computation of these usage times, periods of inactivity of
5 min or longer were subtracted. Usage time did not correlate with
the amount of pre to post or pre to follow-up depression change on
the PHQ-9, p N .20.
3.3. Treatment effects on continuous outcomes at post-assessment
3.3.1. Intention-to-treat analyses
Table 2 presents the observed means of both the ITT and PP
groups; effect sizes and 95% conﬁdence intervals are presented in
Table 3. Between-group effects in the ITT sample on depression se-
verity at post-treatment were in the medium range, conventionally
deﬁned as d = 0.50 (Cohen, 1992). Speciﬁcally, a between-groups
effect of d= 0.57 was observed at post-treatment and a small effect
of d = .33 at follow-up.
Weobserved large pre–post reductions in depression on theprimary
outcome variable (PHQ-9) in the treatment group, with a within-group
pre–post effect size of d = 1.32; for the baseline to follow-up period:
d = 1.13. Depression reduction was also substantial in the control
group, though, with a moderate to large pre–post effect of d = 0.71
on the primary outcome measure (PHQ-9), and a similar moderate to
large baseline to follow-up within-group effect of d= 0.73. MM analy-
ses revealed a signiﬁcant time by treatment condition interaction for the
PHQ-9 at post-treatment in the ITT sample (F1,155.6 = 9.00, p b .01).
Effect sizes for secondary outcomes were smaller than those for de-
pression measures, with the exception that the effect on anxiety (GAD-
7) approached that observed for depression. However, with GAD-7 as
the dependent variable, the interaction between time and treatment screening questionnaire (18/02/2013 - 12/10/2013)
Excluded (n = 122)
Did not provide consent or contact information (n=58)
Could not be reached for interview (n = 18)
Exclusion diagnosis (n = 14)
Suicidal ideation (n = 32)
t inclusion criteria and were randomized
Control Group
(n = 85)
Did not engage with 
rogram (n=22) (28%)
Did not activate 
program access 
voucher (n=8)
Activated voucher 
but completed 
fewer than 4 
modules or spent 
less than 60 
minutes in 
program (n=14)
Completed Post-
Questionnaires 
(n=73) (86%)
Completed Follow-up (6 
Month) Questionnaires
(n=61) (72%)
icipant ﬂow chart.
Table 2
Results of outcome measures: Means and standard deviations.
ITT PP
Pre n
(treat) = 78
n (control)= 85
Post
n (treat) = 60–61
n (control) = 72–73
Follow-up
n (treat) = 54–57
n (control) = 62–64
Pre
n (AV) = 70
n (4S) = 56
Post
n (AV) = 58–59
n (4S) = 51
Follow-up
n (AV) = 52–55
n (4S) = 45–48
Measure ITT
subgroup
Mean SD Mean SD Mean SD PP treatment
subgroup
Mean SD Mean SD Mean SD
Primary outcome
PHQ-9 Treatment 16.62 3.44 10.08 6.37 11.28 6.04 AV 16.56 3.40 9.78 6.15 11.05 6.02
Control 17.20 3.86 13.64 6.14 13.39 6.59 4S 16.54 3.33 9.53 6.35 11.15 6.03
Secondary outcomes
GAD-7 Treatment 13.03 3.77 8.69 5.06 9.19 4.78 AV 13.00 3.74 8.56 5.10 9.07 4.81
Control 13.44 3.90 10.73 5.19 10.61 5.76 4S 13.04 3.76 8.29 5.14 9.06 4.61
PHQ-15 Treatment 13.06 4.65 10.89 5.32 11.67 5.21 AV 12.90 4.70 10.66 5.20 11.45 5.16
Control 12.99 4.51 12.00 5.77 11.98 5.88 4S 12.73 3.92 10.39 5.06 11.46 4.78
SF-12 —
physical
Treatment 45.39 10.72 45.82 9.45 41.60 9.14 AV 45.63 10.74 45.83 9.60 41.93 9.11
Control 43.79 10.45 43.74 11.58 41.88 11.36 4S 46.33 9.80 46.44 9.53 41.80 9.17
SF-12 —
mental
Treatment 25.93 6.95 33.70 11.24 34.58 11.74 AV 25.88 6.62 34.06 11.24 34.90 11.81
Control 24.65 7.31 30.62 11.61 32.89 11.82 4S 25.98 6.22 34.12 11.38 34.88 11.43
ITT: Intention-to-treat sample (data from all subjects); PP: Per-protocol sample (data in treatment group only from subjects who logged on and started at least 4modules); Pre: Pre-treat-
ment, Post: Post-treatment (3month); Follow-up: 6month; PHQ-9: PatientHealth Questionnaire 9-Item; GAD-7:Generalized AnxietyDisorder 7-Item; SF-12: Short FormHealth Survey–
12 Items; AV = activated voucher to access program; 4S: completed at least 4 modules and spent ≥60 min in program.
54 B. Meyer et al. / Internet Interventions 2 (2015) 48–59condition was only marginally signiﬁcant in the ITT sample, F1,150.9 =
3.46, p= .07. No other signiﬁcant interaction effects were observed in
the ITT sample.
3.3.2. Per-protocol analyses
Observed means for the PP groups (PP-AV and PP-4S) are presented
in Table 2; effect sizes and 95% conﬁdence intervals are shown in
Table 3. In general, the effects in the AV and 4S groups were similar in
magnitude, with slightly larger effects among those in the PP-4S
group. Large pre–post depression reductions were observed in the PP
samples, with effects of d= 1.40 for the PHQ-9. Between-group effects
were in the medium-large range for the PP groups.
MM analyses revealed signiﬁcant treatment effects for depression in
both PP groups. That is, in the prediction of PHQ-9 scores at post-
treatment, the interaction between time and treatment group was sig-
niﬁcant for the PP-AV sample, F1,148.8 = 11.07, p b .01, as well as for
the PP-4S sample, F1,136.6 = 11.14, p b .01.
Tables 2 and 3 show that effect sizes for the secondary outcome
measures were somewhat smaller, compared to the primary outcomes.
However, the interaction between time and treatment group in the pre-
diction of GAD-7 reached signiﬁcance, both for the PP-AV group,
F1,145.6 = 4.18, p b .05, and for the PP-4S group, F1,134.6 = 4.86, p b .03.
No other signiﬁcant interaction effects between time and treatment
condition were observed in the PP samples, although in the prediction
of PHQ-15, this interaction was marginally signiﬁcant (p = .08, PP-4S
group).
3.4. Treatment response at post-treatment and follow-up
Of 163 randomized participants, 159 (98%) scored above 10 on the
primary outcome measure (PHQ-9) and were thus included in the re-
sponder analyses. In the ITT sample, 38.2% (n= 29/76) of participants
in the treatment group were classiﬁed as responders at post-
treatment, compared to 16.9% (n = 14/83) of those in the control
group. This difference was statistically signiﬁcant, χ2(1) = 9.11,
p b .01 and corresponded to a number needed to treat (NNT) of 5 (CI-
95% = 2.9–13.0). In the PP-AV sample, at post-treatment, the propor-
tion of participants classiﬁed as responders was 42.6% for the PP-AV
group (n = 29/68; NNT = 4, CI-95% = 2.5–8.7) and 49.1% in the PP-
4S group (n= 27/55; NNT = 4, CI-95% = 2.1–6.0). These proportions
also differed signiﬁcantly from the proportion of 16.9% (n = 14/83)observed in the control group (for the PP-AV group: χ2(1) = 12.20,
p b 0.001; for the PP-4S group: χ2(1) = 16.45, p b .001).
When themore lenient criterion for clinically signiﬁcant change rec-
ommended by Kroenke et al. (Kroenke et al., 2010) was used (5-point
pre–post PHQ-9 decline), response rates were higher. That is, 37% of
control participants responded at post-treatment, compared with 53%
(ITT), 59% (PP-AV), or 63% (PP-4S) in the treatment groups, respective-
ly. The differences between the treatment groups versus control group
were also statistically signiﬁcant when this deﬁnition of post-
treatment response was used, ps b .05.
At follow-up, there were few differences in response rates between
the treatment and control groups, as would be expected, given the
trend toward symptom severity convergence (Table 2). Speciﬁcally,
using the response deﬁnition of at least 50% pre to follow-up PHQ-9
score reduction plus a score of below 10 at follow-up, response rates
did not differ signiﬁcantly between groups. Collapsing across groups,
23% could be classiﬁed as responders according to this deﬁnition in the
ITT groups, and there were no signiﬁcant group differences when the
per-protocol groups were examined. However, when the more lenient
response deﬁnition of at least 5-point PHQ-9 reductionwas used, one sig-
niﬁcant difference was observed. That is, among the treatment-adherent
participants (PP-4S group), 50% were classiﬁed as responders at follow-
up (28/56), whereas this was true for only 32% of control participants
(27/85). This difference was statistically signiﬁcant, χ2(1) = 4.72,
p b 0.05. This corresponds to an NNT of 6 (CI-95% = 2.9–54.9).
3.5. Stability of treatment effects up to 6 months
Tables 2 and 3 show that between-group differences at 6 months
tended to be slightly smaller than those observed at 3 months, and
this was due to a tendency toward convergence between the groups.
For example, whereas participants in the control group reported a slight
reduction on the PHQ-9 between month 3 and 6, on average, PHQ-9
scores in the treatment group rose slightly. To examine the course of
symptom changes from post-treatment to follow-up, we conducted
MM analyses in which only the time-span between post-treatment to
follow-up was considered. These analyses were again conducted in
the ITT group and both PP groups.
With the PHQ-9 as dependent variable, we observed signiﬁcant
main effects for treatment condition, ps b .03, but no signiﬁcant effects
for time in these analyses. This showed that the signiﬁcantly reduced
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55B. Meyer et al. / Internet Interventions 2 (2015) 48–59depression scores in the treatment group remained lower than those in
the control group when the period from 3 to 6 months was considered,
despite the relative convergence ofmeans and reduced between-groups
effect size at follow-up (see Tables 2 and 3). One signiﬁcant interaction
between time and treatment group was observed. That is, in the PP-4S
sample, participants in the treatment group reported a slight increase
in PHQ-9 scores between post-treatment and follow-up, whereas
there was a minimal reduction over this period in the control group,
F1,114.47 = 4.95, p b .03. Even in this subgroup, though, PHQ-9 scores
at six months remained lower in the treatment than the control group
(see Table 2).
Mean comparisons at post-treatment and follow-up were also
conducted and showed that PHQ-9 scores differed signiﬁcantly be-
tween the intervention and control groups at post-treatment, both
in the ITT and PP samples, ps b .01. At follow-up, however, the differ-
ence in PHQ-9 scores was only marginally signiﬁcant in the ITT sam-
ple, t(119)= 1.83, p=0.07, and in the PP-4S sample, t(110) = 1.85,
p = 0.07. In the PP-AV sample, PHQ-9 scores at follow-up were sig-
niﬁcantly lower in the intervention group than the control group,
t(117) = 2.01, p b 0.05.
3.6. Treatment moderators
In line with previous trials, we explored whether diagnostic status1,
initial depression severity, onset age (before vs. after age 21), current
age, education, gender, concurrent psychotherapy, or taking antidepres-
santmedication during the treatment periodmoderated pre–post inter-
vention effects. For this purpose, MM analyses were performed,
focussing on the three-way interaction between time (pre to post-
treatment), condition (intervention vs. control), and the respective
moderator variable. Separate analyses were conducted for the ITT and
both PP groups.
Diagnostic status, initial depression severity, onset age, current age,
gender, education, and receiving psychotherapy during the pre–post pe-
riod did not appear to moderate the effect of treatment condition on
symptom change over 3months, ps N .05. However, reported antidepres-
sant use during the pre–post interval appeared to moderate the treat-
ment effect. That is, there was a signiﬁcant interaction among time,
condition, and antidepressant use, regardless of whether the ITT, PP-
AV, or PP-4S group was considered; for the ITT group: F1,134 = 11.51,
p b .01; for the PP-AV group: F1,132 = 10.88, p b .01; for the PP-4S
group: F1,124 = 8.96, p b .01.
To follow up on the three-way interaction, we examined two-way in-
teractions among thosewith versuswithout antidepressant use in the ITT
group. Among participants who did not use antidepressants in the pre–
post interval, time and condition did not interact signiﬁcantly, p N .5.
Among those who reported concurrent antidepressant use, though, the
interaction between time and condition was signiﬁcant, F1,69 = 18.10,
p b .001. Among treatment group participants on antidepressants, PHQ-
9 scores reduced from 16.89 (SE=0.93) to 8.79 (SE=0.93), on average
(estimated marginal means, ITT group), which is a reduction by 48.0%
from pre-treatment scores. Among control participants on antidepres-
sants, by contrast, PHQ-9 scores reduced from 16.88 (SE = 0.77) to
14.54 (SE= 0.77), on average, corresponding to a 13.9% reduction from
pre to post-treatment. Among participants on antidepressants, PHQ-9
scores did not differ at pre-treatment between the treatment vs. control
groups, F1,69 = 0.001, p N .9, but the groups differed at post-treatment,1 For these analyses, we used a maximally conservative deﬁnition of diagnostic status.
That is, the diagnosis of major depressive disorder (MDD) was only awarded if (1) MINI
diagnostic criteria for major depressive episode were met, (2) the diagnosis was con-
ﬁrmed by the diagnostic algorithm of the PHQ-9 at baseline, (3) the threshold of sum-
score at least 15 on the PHQ-9 was met, and (4) the participant reported having been di-
agnosed with a depressive disorder by a healthcare provider, such as a physician. Using
this approach, 52% (n= 85/163) were diagnosed with MDD. These diagnostic cases were
distributed evenly in the treatment versus control group (52% in the control group with
MDD, vs. 53% in the treatment group, χ2(1) = 0.01, p N .90).
56 B. Meyer et al. / Internet Interventions 2 (2015) 48–59F1,69=16.32, pb .001, and thebetween-groupdifferencewasmaintained
at follow-up, F1,61 = 4.57, p b .04.
3.7. Treatment satisfaction and alliance/helpfulness ratings
Sixty participants in the treatment group completed the adapted
ZUF-8 at post-treatment (missing data for one participant on this
scale). The sum score of the ZUF-8 was 24.17 (SD = 4.82), and the
mean score per item was 3.02 (SD= 0.60), reﬂecting a generally posi-
tive evaluation, on average (4=most positive response; 1=most neg-
ative). The ZUF-8 sum score did not differ signiﬁcantly from that
reported for a normative sample of 664 inpatientswhohad been treated
in psychosomatic hospitals in Germany (M= 25.12; SD= 4.63) (Kriz
et al., 2008). Subjective program evaluation correlated with treatment
response, as measured by percentage symptom reduction (PHQ-9) be-
tween baseline and 3months, r=0.37, p b .01. Patients who responded
to the treatment (N50% pre–post reduction plus post-treatment score
b10 on PHQ-9) were more satisﬁed (M = 26.14, SD = 3.93) than
non-responders (M=22.20, SD=4.94), t(57)= 3.81, p b .01. On aver-
age, nearly 80% endorsed a favourable response (77.5%), indicating gen-
eral satisfaction. For example, 83.3% stated they would probably or
deﬁnitely recommend Deprexis to a friend, and 88.3% rated the quality
of the program as good or excellent.
Sixty-two participants in the treatment group also completed the
HAQ-11 an average of three weeks (M = 21.7 days, SD = 5.9) after
activating their program access voucher. Overall, 71% had a positive
impression of the program's helpfulness after three weeks, as indi-
cated by scores above the response-scale midpoint of zero. A correla-
tion of r= .42 (p b .01) with pre to post-treatment PHQ-9 change and
r= .46 (p b .01) with pre to post-treatment PHQ-9 percentage change
showed that early perceived helpfulness/alliance predicted pre–post
symptom reduction. These correlations remained signiﬁcant when
controlling for baseline symptom severity (PHQ-9 pre-treatment
scores), partial r = .49 with sum-score change, partial r = .47 with
percentage change, ps b .01. In fact, the correlation between the
HAQ-11 and pre–post symptom reduction also remained signiﬁcant
when controlling for early symptom change. That is, n = 49 partici-
pants in the treatment group completed the PHQ-9 twice within
the ﬁrst 35 days within the Deprexis program (on average, ﬁrst PHQ-
9 completed on day of initial log-in; second PHQ-9 after 24.8 days,
SD = 7.4), as doing so is a standard feature of the program. Control-
ling for early PHQ-9 change, as measured by the difference between
these ﬁrst two within-program PHQ-9 scores, the HAQ-11 was still
signiﬁcantly correlated with pre–post PHQ-9 sum score change, par-
tial r = .34, p b .02, and with pre–post PHQ-9 percentage change,
partial r = .40, p b .01.
To explore whether these early alliance ratings could predict clinical
response, a median split was used to classify respondents into those
with clearly positive (HAQ-11 mean score N 1, n = 30, 48%) versus
less positive (HAQ-11 b 1, n = 32, 52%) alliance/helpfulness ratings.
Among those with positive early alliance ratings, 69% (n = 20/29)
achieved clinically signiﬁcant pre–post response (N50% PHQ-9 pre–
post reduction plus post-treatment score below 10), whereas only 25%
(n = 8/32) of those with less positive early alliance ratings achieved
such response, χ2(1) = 11.84, p b .001.
A correlation of r= .60, p b .001 also showed that alliance/helpful-
ness ratings after 3 weeks were strongly associated with overall treat-
ment satisfaction (ZUF-8) after treatment termination.
3.8. Subsidiary analyses: PHQ-9 changes among diagnosed participants
with severe depression
The analyses reported above focussed on all participants included in
this trial, which included those who exceeded the severe depression
threshold (PHQ-9 N 14) at a pre-screening but not necessarily at the
baseline assessment. All of the included participants had exceeded theseverity criterion initially but 25% of them scored below 15 at baseline,
and 13% did notmeet criteria forMDD or DD on theMINI. Therefore, the
question arises whether ﬁndings hold up among participants who
exceeded the severity criterion at baseline aswell andwhowere eligible
for a diagnosis of MDE or DD. Thus, subsidiary analyses were conducted
with this more stringently deﬁned subsample of participants with diag-
nosed depression and severe symptoms at baseline. These analyses fo-
cussed on the trajectory of PHQ-9 symptoms between baseline, post-
treatment, and follow-up. We conducted ITT analyses among this sub-
group with the PHQ-9 serving as dependent variable.
Using the inclusion criteria of conﬁrmedMDE or DD plus baseline se-
verity of PHQ-9 N 14, n=109 (67%) were included. Within this subsam-
ple, 81%were reached at post-treatment and 72% at follow-up. Focussing
on the baseline to post-treatment period, MM analyses yielded a signiﬁ-
cant time by treatment condition interaction, F1,106.3 = 10.23, p b .01.
Mean PHQ-9 scores changed by 7.68 points over this period within the
treatment group, from 18.24 (SD=2.72) to 10.56 (SD=6.26), whereas
in the control group, a mean PHQ-9 reduction of 3.78 points was ob-
served, from 18.76 (SD = 3.11) to 14.98 (SD = 6.40). The within-
groups effect size was very large for the treatment group (d = 1.66,
95% CI: 1.19–2.12), and about half as large (although still large in absolute
terms) for the control group (d=0.78, 95% CI: 0.36–1.20). The between-
groups effect size at post-treatmentwasmoderate to large (d=0.70, 95%
CI: 0.27–1.13).
MeanPHQ-9 scores increased slightly in the treatment groupbetween
post-treatment and follow-up (M = 12.69, SD = 6.34), whereas they
remained slightly higher but stable in the control group (M = 15.00,
SD= 6.53). The pre-to-follow-up within-group effect for the treatment
group was large (d = 1.21, 95% CI: 0.75–1.68) and somewhat smaller
but still substantial for the control group (d= 0.78, 95% CI: 0.36–1.19).
The between-groups effect size at follow-up was small to moderate
(d=0.36, 95% CI:−0.09–0.81).MManalyses focussing on the period be-
tween post-treatment to follow-up showed a signiﬁcant time by treat-
ment condition interaction, F1,79.3 = 5.11, p b .03, suggesting that
symptom trajectories differed between groups over this period. However,
a signiﬁcant treatment group effect suggested that participants in
the treatment group had signiﬁcantly lower depression scores when
scores were collapsed across the post-treatment and follow-up time-
points, F1, 90.4 = 6.45, p b .02.
4. Discussion
The present study aimed to test the effectiveness of the Deprexis
program among adults presentingwith depression symptoms in the se-
vere range, most of whom were receiving heterogeneous forms of con-
current treatment. Of note, we examined the effects of an Internet
intervention without personal support in a population that is compara-
tively difﬁcult to treat, given the elevated symptom severity levels and
high rates of depression chronicity aswell as early onset. Themain ﬁnd-
ings were: (1) that the effectiveness of Deprexis over a 3-month period,
delivered without personal program support, could be replicated, com-
pared to a CAU control condition; (2) that effects on secondary out-
comes such as somatic symptoms and quality of life were weaker,
with the exception of signiﬁcant effects on anxiety in per-protocol anal-
yses (marginally signiﬁcant in ITT analyses); (3) that the treatment ef-
fects on depression severity could be largely maintained up to six
months, although group differences were smaller at that point,
(4) that concurrent antidepressant use might moderate the effects of
the intervention, such that substantial beneﬁt may occur among pa-
tients on antidepressants who use Deprexis as an adjunctive treatment
tool. Additionally, we replicated previous ﬁndings by showing a high
level (around 80%) of patient satisfaction with the program. We also
showed for the ﬁrst time that perceptions of early alliance/helpfulness
after an average of three weeks could predict treatment response over
3 months quite powerfully, even when controlling for early symptom
reduction.
2 Attrition was much lower in the present trial than one might expect for unsupported
Internet interventions. At least two explanations for this seem plausible: Firstly, pre-
treatment diagnostic interviews are rare in trials with unguided interventions, but they
were used here and may have bolstered commitment to participate (Johansson and
Andersson, 2012; Berger et al., 2011). Secondly, the relationship between depression se-
verity and attrition perhaps deserves research attention because the high symptom load
amongmore severely depressed participantsmightmotivate them to use the intervention
more, and complete assessments more diligently, than might be true for their less de-
pressed counterparts.
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ciﬁc effects of theDeprexis programon its intended outcome: depression
reduction. There was also evidence for sustained effects after treatment
discontinuation (i.e. group differences when the post-treatment to
6 month follow-up period was examined), although the differences be-
tween the treatment and control group were smaller at that point, and
responder analyses revealed few signiﬁcant group differences at
follow-up. Several explanations may be invoked for these smaller differ-
ences at follow-up: Firstly, Deprexis usagewas limited to a 90 day period.
Our ﬁndings suggest that this may be too brief and should perhaps be
changed to a longer period, at least for severely depressed individuals.
Secondly, we note that even at 6 months, between-group effect sizes in
the small to medium range were observed for the primary outcome
(i.e. between 0.20 and 0.50). Thirdly, it is important to note that large im-
provements were observed among control participants, which may be
explained, in part, by regression to the mean, although other processes
(e.g. differential treatment-seeking) may also be involved. Indeed, it
seems reasonable to expect that control participants would actively
seek treatment when symptoms do not improve over time, particularly
in a country such as Germany, where a great variety of inpatient and
outpatient treatment services are available at no direct cost to patients
(i.e. covered by mandatory health insurance) (Gaebel et al., 2009).
Thus, the equivalence of the treatment and control groups over longer
periods cannot be assumed, and future investigations should attempt
to disentangle how differential treatment utilization might inﬂuence
symptom trajectories over time.
In summary, though, these results replicate previous ﬁndings by
demonstrating that considerable rates of depression reduction appear
to occur as a consequence of using the program,with effect sizes closely
resembling those observed in previous trials. The ﬁndings also suggest
that the beneﬁt of the program is particularly strong if combined with
antidepressant medication (or possibly with psychotherapy). These
ﬁndings suggest, then, that Deprexis is an effective Internet-based psy-
chological intervention for adults reporting depression symptoms in the
severe range. Given that several previous trials have shown similar ef-
fects, the effects associated with this program can be considered robust,
in our opinion. Among participants who engaged with the program
with reasonable intensity (at least four sessions and at least one hour),
clinically meaningful symptom reductions of at least 5 points on the
PHQ-9 (Kroenke et al., 2010) were observed in nearly 2 out of 3 cases
at post-treatment, even though such change also occurred in the control
condition in about 1 out of 3 cases.
An intriguing preliminary ﬁnding was that effects were particularly
strong among those who were on concurrent antidepressants and
used the program as an adjunctive treatment tool. We can only specu-
late about explanations for this ﬁnding. One potential explanation is
that participants on antidepressants who participated in this trial
were disenchanted with the effects of their medication and, therefore,
strongly desired additional help. Once they received it from the online
intervention, they may have beneﬁtted particularly strongly. Another
possible explanation is that simultaneously receiving antidepressants
and engaging with cognitive–behavioural techniques produces syner-
gistic effects. For example, antidepressants can improve hippocampal
function, which facilitates learning and thus may potentiate the effects
produced by cognitive–behavioural interventions (Craighead, 2014). It
remains to be seen, though, whether this interaction effect can be repli-
cated and, if so, whether broader dissemination of the programas an ad-
junct to antidepressant medication or psychotherapy is a feasible
dissemination avenue. Such combinations of Internet-based and con-
ventional treatments are regarded as promising future directions by
many (Andersson and Titov, 2014). Indeed, the question of when,
how, and for whom psychotherapeutic and pharmacological interven-
tions should be combined is a topic of considerable research interest,
and evidence currently supports the idea that chronically depressed pa-
tients, in particular, may beneﬁt more than others from combination
treatment (Craighead, 2014). Clearly, the ways in which software-based as well as face-to-face psychological interventions should be
combined with pharmacotherapy deserve further research attention.
Our ﬁndings also showed that program users seem to develop a
good sense early on of how helpful the intervention will eventually be
for them, even as early as three weeks after ﬁrst logging on. Early
alliance/helpfulness ratings predicted outcome rather powerfully, con-
sistent with decades of psychotherapy research suggesting that the alli-
ance between patients and therapists is a robust predictor of outcome
(Martin et al., 2000). An emerging literature is examining the role of
the alliance in Internet-based treatments, although most studies have
focussed on interventions in which personal support is included, and
ﬁndings so far seemmixed, with the alliance sometimes predicting out-
come and sometimes only weakly or not at all (Knaevelsrud and
Maercker, 2006; Andersson et al., 2012b). Our ﬁndings suggest that ex-
ploring early impressions of perceived ﬁt, helpfulness or common
ground between patients' perceptions and the program's approach
might be fruitful. Previous research suggests that early alliance ratings
might reﬂect, in part, early symptom change or baseline patient charac-
teristics (Webb et al., 2011; Klein et al., 2003); however, it is notewor-
thy that alliance ratings predicted pre–post symptom reduction even
when controlling for baseline symptom severity and early symptom
change. We acknowledge that the “alliance” between a program user
and a software-program is not equivalent with the human alliance or
emotional bond emerging between a patient andhis or her therapist. In-
stead, what we measured with the adapted HAQ-11 may reﬂect users'
sense of perceived helpfulness, plausibility and personal ﬁt – and
these early impressions appear to be good predictors of ultimate clinical
beneﬁt, even if they are not synonymous with the concept of the thera-
peutic alliance between two persons.
Several strengths aswell as limitations of the trial ought to be noted.
Among the strengths, diagnoses were conﬁrmedwith a validated struc-
tured interview, study attrition rate was low (b20%)2, intervention up-
take was good (80% of those who logged on received what we consider
to be a minimally sufﬁcient “dose”), and the study included a sample
that was larger thanmany other trials in this ﬁeld. However, limitations
must be kept in mind, including limited power to detect small to mod-
erate effects, the limited ability to ensure equivalence between the con-
trol and treatment groups over a longer period of time, lack of outcome
ratings beyond self-reports, relatively short follow-up period, and the
attenuated baseline depression range due to the high initial inclusion
criterion. Some of these limitations will be rectiﬁed in the much larger
EVIDENT trial (Klein et al., 2013), although that trial targets mild to
moderate depressive symptoms. Other Deprexis studies are underway
(e.g., see ClinicalTrials.gov: ISRCTN20165665 and NCT01663649 or Ger-
man Clinical Trials Register [www.drks.de]: DRKS00003564), which
may shed further light on questions such as moderation and mediation
of effects, optimal deployment settings, and robustness of effects when
using rater-based measures and considering longer follow-up periods.
In conclusion, we believe that these ﬁndings contribute to the liter-
ature by replicating and extending effects of an Internet-based depres-
sion intervention and by examining moderators and response
predictors, such as concurrent treatment and early perceived helpful-
ness. More research is needed to address remaining methodological
limitations and to improve our understanding of the psychological and
biological mechanisms that explain how the kinds of treatment effects
we observed unfold.
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